Development
ADMA Biologics, Inc.
ADMA
$18.54
-$0.42-2.22%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -787.87% | 140.26% | 6.16% | 44.50% | 17.91% |
| Total Depreciation and Amortization | 0.36% | -0.24% | 3.18% | 4.98% | 4.00% |
| Total Amortization of Deferred Charges | -1.91% | 4.96% | 40.79% | -1.21% | -49.66% |
| Total Other Non-Cash Items | 950.64% | 6.06% | 24.85% | -14.57% | 7.26% |
| Change in Net Operating Assets | -6.75% | 176.33% | 59.61% | -347,866.67% | 99.90% |
| Cash from Operations | 46.82% | 297.81% | 58.85% | -99.51% | 44.45% |
| Capital Expenditure | -58.23% | 13.29% | 55.13% | 48.12% | -10.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -85.99% | 13.29% | 55.13% | 48.12% | -10.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 32.29% | -10.34% | 5.43% |
| Issuance of Common Stock | -98.64% | 32.34% | -- | -- | -- |
| Repurchase of Common Stock | -63.23% | 7.29% | 64.89% | 69.00% | -380.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 99.98% |
| Cash from Financing | -9,487.10% | 73.01% | 136.91% | -101.04% | 7,535.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.86% | 274.02% | 61.36% | -133.55% | 394.80% |